Enter your email address
Submit
Write your message
Volume 14, Issue 4 (Iranian Journal of Breast Disease 2022)
ijbd 2022, 14(4): 45-61 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hajibabaei S, Sotoodehnejadnematalahi F, Nafisi N, Zeinali S, Azizi M. Inhibitory Effect of miRNA-145 on PD-L1 Expression in Breast Cancer Cell Line. ijbd 2022; 14 (4) :45-61
URL: http://ijbd.ir/article-1-927-en.html
URL: http://ijbd.ir/article-1-927-en.html
Sara Hajibabaei1 
, Fattah Sotoodehnejadnematalahi1 , Nahid Nafisi2 , Sirous Zeinali3 , Masoumeh Azizi *4
, Fattah Sotoodehnejadnematalahi1 , Nahid Nafisi2 , Sirous Zeinali3 , Masoumeh Azizi *4
1- Department of Biology, School of Basic Science, Science and Research Branch, Islamic Azad University, Tehran, Iran
2- Breast Surgery Department, Iran University of Medical Sciences, Tehran, Iran
3- Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
4- Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran ,mazizi528@gmail.com
2- Breast Surgery Department, Iran University of Medical Sciences, Tehran, Iran
3- Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
4- Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran ,
Abstract: (3291 Views)
Introduction: PD-L1 is one of the most important immune control molecules in breast cancer and plays an important role in suppressing the immune system against tumor cells. Controlling the expression of PD-L1 at mRNA level using miRNA inhibitors could be helpful strategy for cancer treatment. In this study, considering the possible role of miR-145 as a tumor suppression in breast cancer, its involvement in reducing PD-L1 expression in breast cancer cell lines has been investigated.
Methods: First, the targeting of miRNA-145 on 3 'UTR of PD-L1 gene was confirmed using bioinformatics software and then by luciferase dual reporter assay. The expression level of miRNA-145 was measured in breast cancer cell lines compared to normal line. After transfection of miRNA-145 into breast cancer cell lines, qRT-PCR was used to evaluate the effect of miRNA-145 on PD-L1 expression.
Results: we showed that decreased expression of miRNA-145 in breast cancer cell lines was directly related to increased PD-L1 expression (r= -0.6175, P value₌0.0457). In addition, increased expression of miRNA-145 in breast cancer cell lines MDA-MB231, BT549 and MCF7 significantly reduced PD-L1 expression (1.938±0.212, 1.784±0.03 and 0.083±0.02 respectively).
Conclusion: Our findings suggest that miRNA-145, by targeting the PD1/PD-L1 pathway and reducing PD-L1 expression, may be a therapeutic agent to prevent the progression of breast cancer.
Methods: First, the targeting of miRNA-145 on 3 'UTR of PD-L1 gene was confirmed using bioinformatics software and then by luciferase dual reporter assay. The expression level of miRNA-145 was measured in breast cancer cell lines compared to normal line. After transfection of miRNA-145 into breast cancer cell lines, qRT-PCR was used to evaluate the effect of miRNA-145 on PD-L1 expression.
Results: we showed that decreased expression of miRNA-145 in breast cancer cell lines was directly related to increased PD-L1 expression (r= -0.6175, P value₌0.0457). In addition, increased expression of miRNA-145 in breast cancer cell lines MDA-MB231, BT549 and MCF7 significantly reduced PD-L1 expression (1.938±0.212, 1.784±0.03 and 0.083±0.02 respectively).
Conclusion: Our findings suggest that miRNA-145, by targeting the PD1/PD-L1 pathway and reducing PD-L1 expression, may be a therapeutic agent to prevent the progression of breast cancer.
Full-Text [PDF 1626 kb]
(1308 Downloads)
Conclusion: Our findings suggest that miRNA-145, by targeting the PD1/PD-L1 pathway and reducing PD-L1 expression, may be a therapeutic agent to prevent the progression of breast cancer.
Type of Study: Research |
Received: 2021/09/1 | Accepted: 2021/11/30 | Published: 2022/02/20
Received: 2021/09/1 | Accepted: 2021/11/30 | Published: 2022/02/20
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
